Attenuated strain bacillus anthracis for developing means of specific prevention of anthrax |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
IPC classes for russian patent Attenuated strain bacillus anthracis for developing means of specific prevention of anthrax (RU 2544951):
 Method for production of bacterial concentrate of probiotic microorganisms consortium / 2544052
Invention relates to biotechnology and may be used as a direct addition starter for probiotic sour cream preparation. The method involves preparation of a nutritional medium where one additionally introduces sodium selenite in an amount of 30-50 mcg/ml, sterilisation and cooling to 35°C, inoculum introduction into the nutritional medium; the inoculum is represented by combined starter based on Bifidobacterium bifidum 83, Lactococcus lactis subspecies cremoris 244, Propionibacterium freudenreichii subspecies shermanii AC-2503 taken at a ratio of 40:30:30, biomass propagation and separation from culture liquid. One performs mixing with a protective medium, dispensing, closuring and freezing.
 Using bacteria of nocardioform actinomycetes group for preparing pharmaceutical composition and method for using this pharmaceutical composition / 2543663
Group of inventions concerns using live bacteria of nocardioform actinomycetes group for preparing a pharmaceutical composition and a method of using this composition. What is characterised is using nocardioform actinomycetes having an ability to survive in animal's macrophages; the live bacteria are attenuated by inactivating a gene, which codes a protein involved in destructing methylhexahydroindanedione propionate for preparing the pharmaceutical composition. The presented method for animal treatment for the purpose of protection against a disorder caused by infection by the bacterium of the nocardioform actinomycetes group, involves administering the pharmaceutical composition containing an effective amount of these bacteria into the animal.
 Synbiotic composition for children for prevention and treatment of diaper skin rash / 2543662
Invention refers to using a preparation containing the strain Bifidobacterium breve and a mixture of two soluble ingredients A and B for preparing a composition for prevention and treatment of diaper skin rash in the children. The content of the carbon ingredient A in the preparation makes 5-95 wt % of total content of the ingredients A and B. The ingredients A and B differ by an average number of monosaccharide carbohydrate links with an average chain length of the ingredient A is at least 5 monosaccharide links less than the average chain length of the ingredient B, and a structure of the monosaccharide carbohydrate links.
 Stimulation method of growth of agricultural plants / 2542484
Method provides for pre-seeding treatment of seeds, soil irrigation and treatment of vegetative parts of plants with cultural liquor of strain Lactobacillus plantarum 60-DEP deposited in the All-Russian State Collection of Strains of Microorganisms, which are used in veterinary science and animal breeding, with a titre of 106 CFU/ml at the consumption of 5-30 ml per 100 ml of water.
 Strain of bacteria desulfovibrio sp. for wastewater treatment from heavy metal ions / 2542402
Strain of bacteria Desulfovibrio sp. A 4/1 is deposited in the Russian Collection of Microorganisms (RCM) under the registration number of RCM B-2820D, and is resistant to heavy metal ions.
Nutrient medium for determining antibiotic susceptibility of legionella pneumophila / 2542390
Nutrient medium comprises enzyme-autolyzate of cattle spleen, monosubstituted potassium phosphate, disubstituted potassium phosphate, potassium gluconate, mesoinosite, soluble starch, gelatin, L-cysteine, iron (III) sodium salt, high-grade ink and distilled water in a predetermined ratio of components.
 Method for production of bacterial concentrate and its application as probiotic biologically active food additive / 2541778
Inventions group relates to biotechnology and may be used for preparing bacterial preparations applicable as probiotic biologically active additives. The bacterial concentrate production method envisages preparation of a nutritional medium, sterilisation and cooling. Inoculum introduction, cell propagation, bacterial mass separation from culture liquid, dispensing and closuring. Into the nutritional medium composition one introduces cedar or linseed oil of fish or ringed seal fat in an amount of 1-1.5% of the medium weight; the inoculum is represented by a Bifidobacterium longum DK-100 strain. The produced bacterial concentrate is used as a probiotic biologically active food additive.
Method for production of dry complex starter for kvass fermentation / 2541758
Method involves preparation of a saccharified brew by way of first grade wheat flour and wheat bran mixing at a ratio of 1:1, the produced mixture brewing with 85-90°C water, maintenance during 45-60 minutes, the mixture cooling to 65-67°C, saccharifying with non-fermented barley or rye malt in an amount of 10% of the mixture weight during 60-90 minutes, yeast autolysate introduction in an amount of 0.1% of the mixture weight to produce a nutritional substrate. Then one performs the substrate weighing out into three fermentative vessels with quadruplication of weighed portion equal to 50 g:200 g:800 g, respectively, three-times' autoclaving with a 24 hours' interval under 1.5 atm during 60 minutes, lactic acid bacteria reproduction in the prepared substrate in three-phase propagation cycle till the final acidity of sodium hydroxide solution with concentration equal to 1 mole/dm3 is equal to16-18 cm3 per 100 cm3 of the brew; the lactic acid bacteria source is represented by prebiotic preparations "Lactobacterin" or "Bifidumbacterin" "Evitalia" or a complex consisting of the said three preparations that are dissolved in 5 cm3 of a sterile physiological solution with each of them transferred into the cooled sterile saccharified brew in an amount of 1 dose of the preparation which is equal to 2×109, 107 and 1.5-2.0×109 CFU, respectively, per 50 g of the substrate. The inoculated nutrient medium is incubated (first phase) during 24 hours at a temperature of 37°C; then one performs the second and the third phases of the propagation cycle by way of dilution of the ripe starter of the previous phase in a four-fold quantity of the sterile saccharified brew for the subsequent phase. Incubation of the subsequent phases of the propagation cycle is performed during 24 hours at a temperature of 37°C till acidity of sodium hydroxide solution with concentration equal to 1 mole/dm3 is 16-18 cm3 per 100 cm3 of the brew. Then one performs the phases mixing with potato starch in an amount equal to the starter weight and Saccharomyces cerevisiae pressed bakery yeast in a dose of 5 g/100 dm3 of the kvass wort, the produced mass drying in a sterile air flow at room temperature till moisture content is equal to 13-14%. The total time of the saccharified brew fermentation is equal to 72 hours.
 Nutrient culture medium for swine erysipelas strain erysipelothrix rhuisipathie / 2541454
Nutrient culture medium for swine erysipelas strain Erysipelothrix rhuisipathie refers to general biotechnology and veterinary microbiology. As a nitrogenous nutrition source, the nutrient medium contains a mixture of fish autolysate and alkaline mussel hydrolysate in the following proportions: alkaline mussel hydrolysate 20-50%; fermentation peptone 1%; potassium phosphate 0.3%; sodium phosphate 1.8%; fish autolysate - the rest.
 Method of obtaining bacterial concentrate of bifidobacteria in liquid form / 2540022
Invention relates to biotechnology and medical industry and can be used in production of bacterial concentrates, biologically active food additives, fermented food products. Method of obtaining bacterial concentrate of bifidobacteria in liquid form includes preparation of nutritional medium with addition of growth components based on clarified cottage cheese whey or on water base with addition of up to 1.5% of glucose, or on soybean whey with addition of lactose in amount 1%. Strain of bifidobacteria B. bifidum 83, activated with β-halactosidase, is introduced into prepared nutritional medium in amount 3-5%, biomass is grown, cooled, poured in containers.
Vaccines for prevention of splenic fever and necrotic stomatitis in animals and method for its preparation / 2524430
Presented vaccine comprises the formalin-inactivated leukocidin-exotoxin obtained from production strain Fusobacterium necrophorum "0-1" Russian Research Institute of Experimental Veterinary Medicine ,1-10% inactivated bacterial mass of the said strain containing 7.0-7.7 billion cells per 1 cm3, glycerol and a mixture of mineral oil "Markol-52" and emulsifier taken in weight ratios of 1:(0.9-1.1), and also the suspension of live spores of splenic fever vaccine strain 55 Russian Research Institute of Veterinary Virology and Microbiology in saline, and adjuvant. The method of production of the vaccine comprises cultivation of the strain Fusobacterium necrophorum "0-1" RRIEVM, its inactivation with formalin, isolation of bacterial mass from the culture medium by centrifugation, isolation from the culture medium of exotoxin - leukocidin, its purification and concentration by ultrafiltration on hollow fibres, adding the suspension of live spores of the splenic fever vaccine strain 55-RRIVVM and saponin, and adding of 1-10% inactivated bacterial mass of strain Fusobacterium necrophorum "0-1" RRIEVM, glycerine and mixture of mineral oil "Markol-52" and emulsifier.
Associated vaccine for prevention of anthrax and necrobacillosis in animals / 2480237
Invention refers to veterinary science and biotechnology, and concerns preparing an associated vaccines for prevention of anthrax and necrobacillosis in animals. The characterized vaccine contains the following ingredients in proportions, wt %: a suspension of living spores of the anthrax vaccine strain 55-VNIIVViM (All-Russian Research Institution of Virology and Microbiology) with the initial concentration of (5-5.2)X107 in physiologic saline 1 cm3 - 1.0-1.2; -saponin - 1.5-2.1; -formalin-inactivated leukocidin - exotoxin with molecular weight 18-20 kDa of the strain of Fusobacterium necrophorum "0-1" VIEV (All-Russian Institution of Experimental Virology with the protein content of 5.5- 6 mg % adsorbed in 12-15% aluminium hydroxide taken in the final concentration of 1.8-2.0% pre-suspended in glycol buffer with pH 8.4-8.6 - the rest.
Method for producing diagnostic anthrax allergen / 2415941
Method provides recovery of a diagnostic anthrax allergen directly from a concentrated suspension of vegetative cells of a vaccine strain Bac. anthracis STI-1. The strain is grown on a nutrient medium based on a muriatic hydrolyzate of a fish flour by deep cultivation. The produced bacterial mass is washed in a separator to produce the concentrated suspension of vegetative cells. An allergenic protein fraction is recovered by alkaline hydrolysis, and the prepared hydrolyzate is fractioned. A protein allergen fraction is recovered from a supernatant of the recovered fraction by fractioning with an acetic acid solution; further the precipitation containing an end product is dissolved, dialyzed to produce a purified anthrax protein allergen. The preparation is presented in liquid and lyophilised forms.
Method for increase of melioidosis antigens protectivity by cytokines / 2376031
Invention is related to the field of medicine, in particular to microbiology and immunology and may be used in development of vaccine against melioidosis. Substance of method consists in the fact that animals are immunised with surface melioidosis complex, which consists of antigen 6 (AG6) and antigen d, which is injected to animals subcutaneously, twice, with interval of 10 days, in doses of 30 mcg by protein for mice or 150 mcg for rats. Simultaneously with primary immunisation recombinant interferon-γ - ingaron is injected in doses 8 ME for mice or 120 ME for rats, and in case of secondary immunisation, recombinant interleukin-2 - roncoleukin in doses of 0.6 mcg for mice or 10 mcg for rats, besides cytokines are injected to animals subcutaneously, daily, simultaneously with immunisation and in the next 2 days. In 21 days after primary immunisation animals are infected with 4-32 LD50 of highly virulent strain 100 of melioidosis causative agent, in 30 days after infection parametres of animal lethality are identified.
Method for immunoprophylaxis of experimental pseudocholera with entrapped antigens burkholderia pseudomallei / 2373955
Invention refers to medicine, particularly to microbiology and immunology and can be used for immunoprophylaxis of pseudocholera. The method involves antigen pretreatment to mice followed by infection and estimating level of protectivity. Antigens Burkholderia pseudomallei are chosen of superficial antigenic fractions: D, C, F, J, H. Herewith the antigen solution in amount 1.5 ml is mixed with phosphatidyl choline approximately 40 mg and cholesterol in the ratio 7:3 to produce liposomes.
Method of obtaining of anthracic protective antigen / 2340356
Plating of the vaccine strain on a sterile nutrient medium with sodium bicarbonate. Thus administer sodium bicarbonate into a nutrient medium throughout an exponential growth phase at 6-8 hours of the vaccine strain planting. After the planting process termination allocation, concentration and sterilisation of a protective antigen is performed on the equipment of ultra-and microstraining.
 Immunogenic composition (versions) based on recombinant intracellular pathogen / 2337707
Presented are immunogenic compositions including recombinant attenuated intracellular pathogens, e.g. Calmette-Guérin bacillus (CGB). Immunogenic composition specifically includes CGB containing sequenced extrachromosomal nucleic acid which includes gene coding large extracellular mycobacteria protein sized 23.5, 30 and/or 32 kDa, thus large extracellular unmerged mycobacteria protein is superexpressed and secreted. Version is immunogenic composition containing recombinant CGB with controlled growth. Introduction of immunogenic compositions in mammal organism is associated with superexpression and secretion of specified proteins causing immune response of organism to introduced antigene.
 Proteins causing alternated immunogenic response and methods for their preparing and using / 2311458
Invention relates to a variant of protein subtilysine from Bacillus amyloliquiefaciens with change Y217L and comprising T-cellular epitope. This T-cellular epitope of indicated variant comprises one or some amino acid changes chosen from group consisting of residues corresponding to positions: 76, 79 and 122 wherein indicated subtilysine variant has optionally change at one or some following positions: 3, 31, 40, 41, 46, 47, 48, 50, 76, 101, 104, 107, 111, 128, 147, 154, 181, 182, 183, 185, 206, 215, 218, 238, 247, 248, 250, 254, 258 and 262. Also, invention relates to DNA molecules that encode subtilysine variants, host-cells containing this DNA, and to compositions used in skin care and containing indicated subtilysine variants. Invention provides preparing subtilysine variants that elicit reduced immunogenic response in human as compared with the parent subtilysine.
 Method for preparing nontoxic anti-anthrax vaccine / 2287581
Invention relates to producing vaccines and describes anti-anthrax vaccine that comprises mutant protein toxin from Bacillus anthracis chosen from mutant PA or mutant LF, or mutant EF or their combinations. Mutations of toxins provide the retained immunogenicity in decreasing the level of their toxicity. For the development of vaccine with reduced reactivity invention proposes recombinant DNA-construction for expression of said protein-toxins. DNA-construction comprises the expressing vector and DNA fragment comprising, in turn, genes encoding the corresponding protein-toxin (PA, LF or EF). Invention describes a method for preparing mutant proteins by using the transformed prokaryotic host. Prepared mutant protein-toxin possessing immunogenic properties and absence of toxicity is used for preparing anti-anthrax vaccine comprising one or more mutant protein-toxins and in combination with protein-toxin PA, LF or EF of wild type. Using the invention provides to develop the safety and effective vaccine against anthrax.
Associated vaccine against anthrax and plague in cattle / 2286173
The suggested vaccine contains suspension of viable spores of anthracic vaccinal strain "55-VNIIBB&M" at initial concentration of 500-700 mln. spores/cu.cm, cultural virus-containing raw material of vaccinal virus of cattle plague of "LT" strain at activity of not less than 7.0 lg TCD50/cu. cm, lactosopeptonic stabilizing agent and distilled water at the following content of components,%: spores of anthracic strain "55-VNIIVV&M" -6.2 - 10.0; cultural raw material of cattle plague virus of "LT" strain -25.0 - 30.0; lactosopeptonic stabilizing agent -48.0 - 50.0; distilled water - the rest. One vaccinal dosage contains about 20-25 mln. anthracic spores and about 4.5-5.5 lg TCD50 of cattle plague virus The suggested vaccine is of high immunogenicity, develops tense immunity in once vaccinated cattle that lasts for 12 mo, not less, moreover, it is areactogenous, safe and stable at storage.
 Method for production of immune serum to virulent strain bacillus anthracis antigen / 2252031
Claimed method includes administering before contamination to the animal subsequently in right pope then after 14 days in left pope 0.2 ml of non-complete Freund's adjuvant with equal volume of physiological salt solution. Subsequent administering after 14 days in right pope up to 10 LD50 of Bacillus anthracis 81/1 spore dredge doesn't cause animal death for long period (monitoring time is 35 days).
|
FIELD: biotechnology. SUBSTANCE: strain of B. anthracis 363/11 is deposited in the collection of strains of microorganisms of State Scientific Institution of Russian National Research Institute of Veterinary Virology and Microbiology of Russian Agricultural Academy No. 363. The strain is made for developing the means of specific prevention of anthrax. EFFECT: invention enables to expand the range of protective action, to increase immunogenicity, to reduce immunising dose and reactogenicity of the vaccine strain against anthrax. 5 tbl, 5 ex
The invention relates to the field of veterinary Microbiology, concerns paskapallero natural weakened strain of Bacillus anthracis 363/11 and can be used in research and biotechnological centers for specific prophylaxis of anthrax. Due to the wide spread of anthrax in the territory of the Russian Federation in the past and the ability of spores of anthrax microbe to survive in soil pockets of tens and even hundreds of years of prosperity on this disease mainly maintained through universal vaccination of farm animals. In spite of this in Russia annually from 2 to 16 sporadic cases of anthrax among susceptible animals, most of which were subjected to prophylactic immunization. The main causes of anthrax outbreaks can be attributed to inefficient vaccinated, violation of the conditions of storage of biologics and circulation in nature isolates, immunological not relevant applied to vaccine strains [Y. O. Selyaninov, I. Y. Yegorov, 2012]. Currently in the Russian Federation to ensure the biological security of anthrax infection in livestock is used live vaccine from paskapallero avirulent vaccine strain 5-Vniivvim, and in healthcare - from paskapallero vaccine strain STI-1. Abroad for the prevention of this disease in animals and humans use vaccines from strains of B. anthracis Sterne (34 F2), Weybridge (Europe, USA etc.), Ihtiman, Bulgaria, K79Z (Ukraine), 1190-R (Romania) and others. [Gennady Onishchenko et al., 1999]. All of these vaccine strains do not contain the plasmid pXO2, responsible for the production of a capsule, a major pathogenicity factor of the anthrax microbe. Obtaining strains of B. anthracis, are promising for the creation on their basis of live vaccines, conducted in two main ways: artificial elimination of plasmid pXO2 the weakened capsulorraphy strains with subsequent selection backupsonline variants and selection backupsonline strains of B. anthracis from natural weakened field isolates. The first method of virulent capsulorraphy isolates anthrax microbe were received vaccine strains 1190-R (1934), Sterne (1937), Weybridge (1939), Takahaschi (1939), Mukteswar (1939), STI (1940), NIIEG K-II (1940), Shuya-15 (1949), the second strain Ihtiman and 55-Vniivvim [E. N. Shlyakhov, 1960; By R. S., 1967; G. Onischenko et al., 1999]. However, in a comparative study of the specific activity of the most well-known vaccine strains (STI, GNKI, Ihtiman, 34-F2, 55-Vniivvim) was statistically significant and substantial difference in their immunogenicity and protective spectra relative to n�which field isolates until full exposure to infection [I. A. Bakulev, V. Gavrilov, 1991]. To overcome these drawbacks, the authors propose to use chemical vaccines based on protective antigen, combination vaccines on the basis of the dispute one strain and protective antigen of another strain, bi - and trivalent vaccines based on different strains, and searching for new strains possessing the full antigenic composition. Close analog of the present invention is backupsonline an avirulent strain 55-Vniivvim obtained by selection in Vniivvim of isolate C-63, by designated staff of Kharkov Zoological veterinary Institute of dead pig in 1963, and used for the manufacture of a vaccine against anthrax in animals. Strain 55-Vniivvim in prilivnykh doses of 12.5×107and 25.0×107spores induces the production of the stress protivovirusnogo immune system of vaccinated animals (cattle and cattle, respectively) and protects from 40 to 100% of population from infection with virulent field isolates [I. A. Bakulev, V. Gavrilov, 1991]. The disadvantages of this strain is its low antigenicity, not a wide range of protective action against field isolates circulating in Russia and residual reactogenicity. Upon receipt of the IRB�reasonig hyperimmune sera using 4 different schemes of immunization antibody titers to antigens of strain 55-Vniivvim in all cases were 2-8 times lower than to antigens of strain Sterne (34F2). The study staff wildebeest Vniivvim genomic polymorphism of the Museum of cultures of B. anthracis showed that some of them have unique genotypes that differ substantially from molecular types of the majority of the studied isolates of anthrax, including strain 55-Vniivvim. So the isolates in Udmurt SSR in 1989, differing in genotype of strain 55-Vniivvim, caused the disease of cattle a month after his immunization vaccine from strain 55-Vniivvim. About the presence of the vaccine strain 55-Vniivvim reactogenicity reports veterinary specialists of postvaccinal complications in goats education serous edema at the site of application. The aim of the invention is to provide a new an avirulent strain of Bacillus anthracis, has a wide range of protective actions that are more immunogenic and less, compared to the strain-analogue, reactogenicity and immunization dose. This object is achieved by allocating a new natural weakened paskapallero strain of the anthrax microbe. The inventive strain 363/11 dedicated staff wildebeest Vniivvim in 2011 from a fallen gilt. Strain 363/11 deposited in the Collection of strains of microorganisms wildebeest Vniivvim RAAS under inv. �363. The strain Bacillus anthracis 363/11 characterized by the following cultural, morphological, immunological and biochemical characteristics. Cultural properties. Facultative aerobe. Optimum temperature for growth on solid and liquid nutrient media (36±1)°C, optimum pH (7,4±0,2). Is typical for the species B. anthracis cultural and morphological properties when cultured in a liquid nutrient media broth remains clear, the bottom is formed precipitate in the form of a lump of wool; on solid nutrient media forms matte, rough colony R-, less than RO-shape, with a diameter of 3-4 mm On media containing serum of horses and in the presence of CO2and in the body of a susceptible laboratory animals does not form a capsular polypeptide. Morphological properties. Exists in two morphological forms: vegetative and spore. In smears from culture media of gram-positive bacilli are in the form of long chains, which in their joints look chopped off or slightly concave. Spores stained by Ziehl-Nielsen, are oval in shape, are located predominantly Central. Cells do not have flagella, motionless. In vivo (in the body of white mice) forms a chain consisting of 4, 8, 16, 21 or more segments. Biochemical properties. Causes of α-hemolysis of sheep erythrocytes. Fe�mentioed with the formation of acid without the newspaper cellobiose, sucrose, trehalose. Decompose arginine. Oxidizes glucose to acetoin. Restores the nitrate to nitrite. Produces catalase, does not form alkaline phosphatase. Antigenic properties. Somatic antigen of strain 363/11 obtained by termextraction, engages in specific interaction with anthrax precipitating serum, and supernatant daily broth culture - globulin protivoseborainey from the blood serum of horses. After subcutaneous administration to sheep spore suspension of the strain induces production of agglutinating antibodies. Weakly sensitive to the effects of anthrax phage Fah-Vniivvim and highly sensitive to phage Rd/Ph/6. Plasmid composition. Contains in the genome sequence pag - gene, capsular genes of the operon are absent (pXO1+pXO2-). Residual virulence. LD50for outbred white mice body weight 18-20 g is 3,162×105the dispute, for Guinea pigs with a live weight of 200-300 g - over 108argument. Reversibility. Does not restore the ability to capsulorraphy for 7 consecutive passages in Guinea pigs (8 passage ceases to proliferate in the body of Guinea pigs) and 10 passages on outbred white mice. Reactogenicity. Laboratorian for Guinea pigs: after subcutaneous administration of 107disputed the injection formed serous edema, rarely with subsequent ulceration. Not reactogenic for sheep when administered 107dispute subcutaneously in the area of hairless plot armpits. Immunogenic properties. In pravilnoy a dose of 106-107argument causes the formation of vaccinated animals (Guinea pigs, sheep) busy immunity against capsulorraphy reference infecting strains (II vaccine of Zenkovskogo, 17JB) and field isolates. To confirm the advantages of the present invention, specific examples of its implementation. Example 1. Description of the main biological properties of the vaccine strain 55-Vniivvim and paskapallero natural weakened strain 363/11. Characterization of biological properties of strains 55-Vniivvim and 363/11 presented in table 1.
Presented in table 1 data indicate that both strains of properties typical of vaccine strains (permanent loss of capsulorraphy). Differences between strains lies in the ability in vitro to Express the different types of hemolysins at different levels. Example 2 The residual virulence of the strains 55-Vniivvim and 363/11 defined on the model outbred white mice body weight 18-20 g andsea pigs with a live weight of 200-300 g by subcutaneous inoculation in the last volume of 0.25 cm 3spore suspensions serial dilutions of pathogens, cooked with five-time step. The observation of the animals was conducted over 10 days. At the end of the observation period was determined by the ratio of the number of animals that died from the administration of a given dose, the total number of animals, which was introduced this dose. The magnitude of LD50was calculated by the formula Kerber modified by I. P. Ashmarin and A. A. Vorobyov (PL.2).
The data in table 2 indicate that both strains are characterized by a similar indices LD50for Guinea pigs and avirulent strains. For the record� LD 50for outbred white mice strains 363/11 and 55-Vniivvim have differences, but on the classification of E. N. Shlahova and E. V. Cargo (1978) both strains also belong to the group of avirulent cultures. Example 3. In experiments on Guinea pigs defined indicators immunization doses strains 55-Vniivvim and 363/11 protecting from the death of 50% of vaccinated animals (IPD50) after infection reference infecting the culture of the anthrax microbe strain No. 71/12 at a dose of 200 LD50. The results of a comparative assay with Guinea pigs IPD50strains of B. anthracis 55-Vniivvim and 363/11 given in table.3.
The data of table 3 indicate that the rate of IPD50for strain 363/11 10 times lower than for strain 55-Vniivvim, i.e. for induction in Guinea pigs and protective�of immunity, protects 50% of vaccinated animals from death after the introduction of spores of the strain No. 71/12 at a dose of 200 LD50requires 10 times lower dose vaccinates. Example 4. In experiments on Guinea pigs shows that the spectrum of the protective effect of strain 363/11 wider than the strain 55-Vniivvim. The survival rate of vaccinated strain 363/11 Guinea pigs, infected reference infecting cultures of the anthrax microbe (Nos. 71/12, 17JB, 76) and field isolates, isolated in different regions and at different times(№№81, 304, 364), was higher than for Guinea pigs vaccinated with strain 55-Vniivvim (PL. 4).
From table 4 data show that vaccination of animals strain 363/11 protects 100, 50 and 40 percent of Guinea pigs against infection with virulent cultures of field isolates of B. anthracis strains No. 81, 304, 364, respectively, while the percentage of protection of vaccinated animals strain 55-Vniivvim for the specified field isolates is 40, 25 and 10%, respectively. Immunogenic activity of the strains 363/11 and 55-Vniivvim in relation to the reference infecting cultures of strains No. 71/12, 17JB, 76 differences had not. Example 5. Immunogenic activity of the strains was determined in experiments on sheep age 1-1,5 years from the herd, not exposed to vacci�ation against anthrax. The sheep were injected under the skin of 10-12 million spores of strains tested in a volume of 1 ml. After 21 days of vaccinated sheep were infected by intradermal introduction of spore cultures vysokovalentnyh anthrax strains in doses of for sheep certainly not less than 10 lethal doses. Observation of infected animals led within 10 days. Sheep that have formed tight immunity against the infecting strain, remained clinically healthy. Unprotected animals died within 3-5 days after infection with signs of the acute form of anthrax. The specific nature of the death of the sheep was confirmed by microscopy of blood smears and bacteriological analysis.
These tables show that the spectrum of the protective effect of strain 363/11 wider than that of strain 55-Vniivvim. I.e. immunization of animals with the strain 363/11, unlike strain 55-Vniivvim protects them from contamination by field isolates of B. anthracis, immunological not corresponding to the strain 55-Vniivvim (No. 304 and 81). Sources of information 1. Ashmarin, I. P. Statistical methods in microbiological studies / I. P. Ashmarin, A. A. Vorobyov. - L.: Medgiz, 1962. - P. 85. 2. Bakalov, I. A. anthrax Immunization of animals /I. A. Bakulev, V. Gavrilov // Keep, agricultural science. - 1991. - No. 8. - P. 128-131. 3. Selyaninov, J. O. About some of the reasons for the lack of effectiveness of measures for specific prophylaxis of anthrax in Russia / Y. O. Selyaninov, I. Y. Egorova // Actual problems of diseases common to humans and animals: Mater. All-Russia. nauch.-practical use. Conf. with Intern. participants. - Stavropol. - 2012. - P. 69-70. 4. Anthrax: topical aspects of Microbiology, epidemiology, clinical manifestations, diagnosis, treatment and prevention / Onishchenko G. G. [et al.], M.: students a whole MOH, 1999. - 448 p. 5. Shlyakhov, E. N. Epidemiology, dia�suspects and prevention of anthrax / E. N. Shlyakhov. - Chisinau: Protection Of Moldoveneasca, 1960. - 116 p. 6. Shlyakhov, E. N. Titration LD50in mice as a method of determining the virulence of the anthrax bacilli / E. N. Shlyakhov, E. V. Cargo // Achievements and prospects of combating anthrax in the Soviet Union: Mater. X plenary session of the interdepartmental Commission to combat anthrax. - M., 1978. - P. 97-99. 7. By, R. S. Etude comparative de la propriete oedematogene L une nouvelle souche acapsulogene de Bacillus anthracis (souche Ihtiman) / By R. S. // Arch. Inst. Pasteur, Tunis. - 1967. - V. 44, No. 2-3. - P. 229-233. Attenuated strain 363/11 B. anthracis funds for the development of specific prophylaxis of anthrax, deposited in the Collection of microorganisms SSI-Russian scientific research Institute of veterinary Virology and Microbiology of Russia under No. 363.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||